全球肝病登记系统的系统综述:设计、管理和可持续性实践
A systematic review of liver disease registries across the globe: design, management and sustainability practices
一项全球肝病登记系统的系统综述分析了其设计模式、管理机制和可持续性实践。研究涵盖了中国乙肝登记(CR-HepB)、中国急性慢性肝衰竭登记(CATCH-LIFE)、丹麦丙型肝炎登记及欧洲罕见肝病登记等多个实例,为肝病患者注册研究的规范化和持续发展提供参考。
Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79, 516–537 (2023).
Sarin, S. K. et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 5, 167–228 (2020).
Sun, J., Tanaka, J. & Valenti, L. The changing epidemiology of liver diseases in Asia. Liver Int. 42, 1926–1929 (2022).
Younossi, Z. M. et al. Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) registry. Clin. Gastroenterol. Hepatol. 20, 2296–2306.e6 (2022).
Hoque, D. M. E., Sampurno, F., Ruseckaite, R., Lorgelly, P. & Evans, S. M. Study protocol of an equivalence randomized controlled trial to evaluate the effectiveness of three different approaches to collecting Patient Reported Outcome Measures (PROMs) data using the Prostate Cancer Outcomes Registry-Victoria (PCOR-VIC). BMC Health Serv. Res. 17, 75 (2017).
Pericleous, M., Kelly, C., Schilsky, M., Dhawan, A. & Ala, A. Defining and characterising a toolkit for the development of a successful European registry for rare liver diseases: a model for building a rare disease registry. Clin. Med. 22, 340–347 (2022).
McGettigan, P. et al. Patient registries: an underused resource for medicines evaluation : operational proposals for increasing the use of patient registries in regulatory assessments. Drug Saf. 42, 1343–1351 (2019).
Nelson, E. C. et al. Patient focused registries can improve health, care, and science. BMJ 354, i3319 (2016).
Rubinger, L., Ekhtiari, S., Gazendam, A. & Bhandari, M. Registries: Big data, bigger problems?. Injury 54(Suppl 3), S39–S42 (2023).
Lazem, M. & Sheikhtaheri, A. Barriers and facilitators for disease registry systems: a mixed-method study. BMC Med. Inform. Decis. Mak. 22, 97 (2022).
Pop, B. et al. The role of medical registries, potential applications and limitations. Med. Pharm. Rep. 92, 7–14 (2019).
Viviani, L., Zolin, A., Mehta, A. & Olesen, H. V. The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry. Orphanet J. Rare Dis. 9, 81 (2014).
Vento, S. & Cainelli, F. Acute liver failure in low-income and middle-income countries. Lancet Gastroenterol. Hepatol. 8, 1035–1045 (2023).
Nario, S. et al. A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection. JGH Open 5, 669–672 (2021).
Xu, X. Q. et al. Ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China: a CR-HepB-based real-world study. Zhonghua Gan Zang Bing. Za Zhi 31, 698–704 (2023).
Lau, F. F. et al. Ischemic heart disease in chronic hepatitis B: a Danish nationwide cohort study. Clin. Epidemiol. 14, 879–888 (2022).
Lazarus, J. V. et al. European ‘NAFLD Preparedness Index’—is Europe ready to meet the challenge of fatty liver disease?. JHEP Rep. 3, 100234 (2021).
Ornos, E. D., Murillo, K. J. & Ong, J. P. Liver diseases: perspective from the Philippines. Ann. Hepatol. 28, 101085 (2023).
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151, 264–269 (2009). W64.
Valizadeh, A. et al. Abstract screening using the automated tool Rayyan: results of effectiveness in three diagnostic test accuracy systematic reviews. BMC Med. Res. Methodol. 22, 160 (2022).
Jiang, Z. G. et al. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. Liver Int. 36, 1213–1220 (2016).
Jiang, Z. G. et al. Genetic determinants of circulating lipoproteins in nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 52, 444 (2018).
Shan, S. et al. China Registry of Hepatitis B (CR-HepB): protocol and implementation of a nationwide hospital-based registry of hepatitis B. Scand. J. Public Health 48, 233–239 (2020).
Shan, S. et al. Baseline characteristics and treatment patterns of the patients recruited to the china registry of hepatitis B. J. Clin. Transl. Hepatol. 7, 322–328 (2019).
Gu, W. Y. et al. Acute-on-chronic liver failure in China: rationale for developing a patient registry and baseline characteristics. Am. J. Epidemiol. 187, 1829–1839 (2018).
Qiao, L. et al. Cohort profile: a multicentre prospective validation cohort of the Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study. BMJ open 11, e037793 (2021).
Sølund, C. et al. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. Scand. J. Gastroenterol. 53, 849–856 (2018).
Sølund, C. et al. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations. PLoS ONE 9, e113034 (2014).
Hallager, S. et al. Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. CLEP 9, 501–516 (2017).
Hallager, S. et al. Mortality rates in patients with chronic hepatitis C and cirrhosis compared with the general population: a Danish cohort study. J. Infect. Dis. 215, 192–201 (2017).
Nielsen, S. et al. Hepatitis C prevalence in Denmark in 2016—an updated estimate using multiple national registers. PLoS ONE 15, e0238203 (2020).
Carr, B. I., Guerra, V., Donghia, R. & Yilmaz, S. Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes. Ann. Med. Surg. 66, 102458 (2021).
Hagström, H., Shang, Y., Wester, A. & Widman, L. Cohort profile: decoding the epidemiology of liver disease in Sweden (DELIVER). Scand. J. Gastroenterol. 57, 978–983 (2022).
Alexopoulos, A. et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology 74, 1220–1233 (2021).
Hardy, T. et al. The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp. Clin. Trials 98, 106175 (2020).
Huber, Y. et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin. Gastroenterol. Hepatol. 17, 2085–2092.e1 (2019).
McTeer, M. et al. Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information. PLoS ONE 19, e0299487 (2024).
Mann, J. P. et al. European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemp. Clin. Trials 75, 67–71 (2018).
Dakhoul, L. et al. Older age and disease duration are highly associated with hepatocellular carcinoma in patients with autoimmune hepatitis. Dig. Dis. Sci. 64, 1705–1710 (2019).
Hinrichsen, H. et al. Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry. Eur. J. Gastroenterol. Hepatol. 33, 415–423 (2020).
Siederdissen et al. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United Eur. Gastroenterol. J. 6, 213–224 (2018).
Tacke, F. et al. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int. 37, 205–211 (2017).
Hüppe, D. et al. The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). J. Viral Hepat. 28, 1474–1483 (2021).
Christensen, S. et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?. Addiction 113, 868–882 (2018).
Christensen, S. et al. Alcohol and cannabis consumption does not diminish cure rates in a real-world cohort of chronic hepatitis C virus infected patients on opioid substitution therapy—data from the German Hepatitis C-Registry (DHC-R). Subst. Abuse Res. Treat. 13, 1178221819835847 (2019).
Tacke, F. et al. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: data from the German Hepatitis C-Registry. Hepatol. Commun. 6, 2488–2495 (2022).
Bischoff, J. et al. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry. HIV Clin. trials 19, 225–234 (2018).
Ohlendorf, V. et al. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). J. Viral Hepat. 28, 1206–1218 (2021).
Rau, M. et al. Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry. PLoS ONE 17, e0264741 (2022).
Sarrazin, C. et al. Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015. Z. Gastroenterol. 57, 584–592 (2019).
Stein, K. et al. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). Eur. J. Gastroenterol. Hepatol. 34, 76–83 (2022).
Krüger, K. et al. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry. Eur. J. Gastroenterol. Hepatol. 31, 230–240 (2019).
Bischoff, J. et al. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?. HIV Med. 19, 299–307 (2018).
Cornberg, M. et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment. Pharmacol. Ther. 45, 688–700 (2017).
Dultz, G. et al. Effectiveness and safety of direct-acting antiviral combination therapies for treatment of hepatitis C virus in elderly patients: results from the German Hepatitis C Registry. Drugs Aging 35, 843–857 (2018).
Wiegand, J. et al. Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). Eur. J. Gastroenterol. Hepatol. 31, 1424–1431 (2019).
Weinmann, A. et al. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. J. Clin. Gastroenterol. 48, 279–289 (2014).
Schmitt, A. et al. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R). Z. Gastroenterol. 58, 341–351 (2020).
Younossi, Z. M. et al. Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver RegistryTM. J. Viral Hepat. 30, 335–344 (2023).
Yilmaz, Y. et al. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. Aliment. Pharmacol. Ther. 57, 215–223 (2023).
Tan, E. X. et al. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metab.: Clin. Exp. 126, 154911 (2022).
Harris, A. M. et al. Hepatitis B testing, care linkage, and vaccination coverage within a registry of hepatitis C infected patients. Vaccine 37, 2188–2193 (2019).
Børresen, M. L. et al. Hepatitis B prevalence and incidence in Greenland: a population-based cohort study. Am. J. Epidemiol. 181, 422–430 (2015).
Skladany, L. et al. Adherence to oral nutritional supplements after being discharged from the hospital is low but improves outcome in patients with advanced chronic liver disease. Patient Prefer. Adherence 14, 2559–2572 (2021).
Skladany, L. et al. Frailty in nonalcoholic fatty liver cirrhosis: a comparison with alcoholic cirrhosis, risk patterns, and impact on prognosis. Can. J. Gastroenterol. Hepatol. 2021, 5576531 (2021).
Skladany, L. et al. Applicability and prognostic value of frailty assessment tools among hospitalized patients with advanced chronic liver disease. Croatian Med. J. 62, 8–16 (2021).
Skladaný, Ľ et al. Comparison of the quality of life of patients with liver cirrhosis before and during the COVID-19 lockdown in Slovakia. Sci. Rep. 13, 2463 (2023).
DeSilva, M. B., Settgast, A., Chrenka, E., Kodet, A. J. & Walker, P. F. Improving care for patients with chronic hepatitis B via establishment of a disease registry. Am. J. Trop. Med. Hyg. 107, 198–203 (2022).
Mokdad, A. A., Singal, A. G., Marrero, J. A., Zhu, H. & Yopp, A. C. Vascular invasion and metastasis is predictive of outcome in Barcelona clinic liver cancer stage C hepatocellular Carcinoma. J. Natl. Compr. Cancer Netw. 15, 197–204 (2017).
Park, H. et al. Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection. Sci. Rep. 12, 18094 (2022).
Reddy, K. R. et al. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment. Pharmacol. Ther. 45, 115–126 (2017).
Younossi, Z. M. et al. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naïve patients with hepatitis C. AJMC https://www.ajmc.com/view/real-world-outcomes-of-ledipasvir-sofosbuvir-in-treatment-naive-patients-with-hepatitis-c (2016).
Abu-Dayyeh, I. et al. Patterns and trends of hepatitis C virus infection in Jordan: an observational study. Front. Public Health 11, 1280427 (2023).
White, L. et al. Facilitating treatment of HCV in primary care in regional Australia: closing the access gap. Frontline Gastroenterol. 10, 210–216 (2019).
Gray, E. et al. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection. J. Viral Hepat. 23, 677–686 (2016).
Gray, E., Pasta, D. J., Norris, S. & O’Leary, A. Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry. BMC Health Serv. Res. 17, 288 (2017).
Pelizzaro, F. et al. Transarterial chemoembolization for hepatocellular carcinoma in clinical practice: temporal trends and survival outcomes of an iterative treatment. Front. Oncol. 12, 822507 (2022).
Pelizzaro, F. et al. Monofocal hepatocellular carcinoma: How much does size matter?. Liver Int. 41, 396–407 (2021).
Pelizzaro, F. et al. Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients. Cancers 13, 897 (2021).
Campani, C. et al. Time-varying mHAP-III is the most accurate predictor of survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Liver Cancer 10, 126–136 (2021).
Bucci, L. et al. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 37, 259–270 (2017).
Garuti, F. et al. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 41, 585–597 (2021).
Giannini, E. G. et al. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digest. Liver Dis. 54, 1215–1221 (2022).
Giannini, E. G. et al. Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice. Hepatology 67, 1784–1796 (2018).
Reggidori, N. et al. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs. JHEP Rep. 5, 100784 (2023).
Cucchetti, A. et al. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. Eur. J. Cancer 158, 100784 (2021).
Trevisani, F. & Giannini, E. G. The ITA.LI.CA Consortium: How multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence. Ann. Hepatol. 27(Suppl 1), 100564 (2022).
Fujii, H. et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin. Gastroenterol. Hepatol. 21, 370–379 (2023).
Kaze, E. & Henrion, J. 5-year mortality of alcohol-related cirrhosis: patients die just as much but not in the same manner. Acta Gastro-Enterol. Belg. 85, 370–379 (2022).
Kaze, E. & Henrion, J. Clinical characteristics of hepatocellular carcinoma in patients with cirrhosis: a comparative cohort study. Acta Gastro-Enterol. Belg. 86, 412–416 (2023).
Yen, Y. H. et al. Real world clinical practice in treating advanced hepatocellular carcinoma: when East meets West. PLoS ONE 15, e0230005 (2020).
Liu, Y.-W. et al. Prognosis after resection of single large hepatocellular carcinoma: results from an Asian high-volume liver surgery center. PLoS ONE 15, e0230897 (2020).
Sinn, D. H., Gwak, G.-Y., Cho, J., Paik, S. W. & Yoo, B. C. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. PLoS ONE 9, e112184 (2014).
Cho, H. J. et al. A proposal for modification of the barcelona clinic liver cancer staging system considering the prognostic implication of performance status. Gut liver 13, 557–568 (2019).
Bessone, F. et al. Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries. Arch. Toxicol. 97, 593–602 (2023).
Kudo, M. et al. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver cancer 5, 190–197 (2016).
Noronha, F. C. et al. Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis. Dig. Dis. Sci. 64, 2671–2683 (2019).
Allard, M. A. et al. Long-term outcomes of patients with 10 or more colorectal liver metastases. Br. J. Cancer 117, 604–611 (2017).
Viganò, L. et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. a LiverMetSurvey-based study of 6,025 patients. Ann. Surg. Oncol. 21, 1276–1286 (2014).
Serenari, M. et al. The effect of a liver transplant program on the outcomes of resectable hepatocellular carcinoma: a nationwide multicenter analysis. Ann. Surg. 277, 664–671 (2023).
Famularo, S. et al. Machine learning predictive model to guide treatment allocation for recurrent hepatocellular carcinoma after surgery. JAMA Surg. 158, 192–202 (2023).
Stvilia, K. et al. Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia. Public health 195, 42–50 (2021).
Averhoff, F. et al. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J. Hepatol. 72, 680–687 (2020).
Docherty, M. et al. Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis. J. Am. Med. Inform. Assoc. 28, 1235–1241 (2021).
Woreta, T. A. et al. Validation of the accuracy of the FASTTM score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS ONE 17, e0266859 (2022).
Kleiner, D. E. et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw. open 2, e1912565 (2019).
Puri, P. et al. Alcohol consumption is associated with the severity and outcome of acute liver injury/failure. Liver Int. 40, 360–367 (2020).
Rubin, J. B., Hameed, B., Gottfried, M., Lee, W. M. & Sarkar, M. Acetaminophen-induced acute liver failure is more common and more severe in women. Clin. Gastroenterol. Hepatol. 16, 936–946 (2018).
Camarata, M. A. et al. Outcomes of acute liver injury in adults due to Wilson’s disease: is survival without transplant possible?. Liver Transplant. 26, 330–336 (2020).
Cardoso, F. S. et al. Persistent but not transient acute kidney injury was associated with lower transplant-free survival in patients with acute liver failure: a multicenter cohort study. Crit. Care Med. 50, 1329–1338 (2022).
Rao, A. et al. Secular trends in severe idiosyncratic drug-induced liver injury in North America: an update from the Acute Liver Failure Study Group Registry. Am. J. Gastroenterol. 117, 617–626 (2022).
Kendall, C. E. et al. A cross-sectional study of prolonged disengagement from clinic among people with HCV receiving care in a low-threshold, multidisciplinary clinic. Can. Liver J. 3, 212–223 (2020).
Assal, A., Mackie, D. & Cooper, C. L. Transient elastography, APRI, and ultrasound have minimal utility in chronic low-replicative hepatitis B infection. Eur. J. Gastroenterol. Hepatol. 26, S25–S31 (2014).
Alonso, E. M., James, L. P., Zhang, S. & Squires, R. H. Acetaminophen adducts detected in serum of pediatric patients with acute liver failure. J. Pediatr. Gastroenterol. Nutr. 61, 102–107 (2015).
Huang, C. F. et al. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol. Int. 13, 587–598 (2019).
Wong, Y. J. et al. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study. Hepatol. Int. 17, 1150–1161 (2023).
Okushin, K. et al. The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL). Sci. Rep. 14, 2826 (2024).
Okushin, K. et al. Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). J. Gastroenterol. 57, 587–597 (2022).
Curran, C., Stanley, A. J., Barclay, S. T., Priest, M. & Graham, J. The association between deprivation and the incidence and survival of patients with hepatocellular carcinoma in the West of Scotland. Expert Rev. Gastroenterol. Hepatol. 15, 1427–1433 (2021).
Osinubi, A. et al. Evaluation of the performance of algorithms that use serial hepatitis C RNA Tests to predict treatment initiation and sustained virological response among patients infected with hepatitis C virus. Am. J. Epidemiol. 188, 555–561 (2019).
Cabibbo, G. et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment. Pharmacol. Ther. 46, 688–695 (2017).
Lee, M. W. et al. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma <3 cm: emphasis on association of local tumor progression and overall survival. Eur. Radiol. 30, 2391–2400 (2020).
Bae, B. K. et al. Trends in radiotherapy administration in the management of hepatocellular carcinoma: analysis of a Korean tertiary hospital registry of hepatocellular carcinoma patients diagnosed between 2005 and 2017. Front. Oncol. 12, 928119 (2022).
Bae, B. K., Yu, J. I., Park, H. C., Goh, M. J. & Paik, Y. H. Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017. Radiat. Oncol. J. 41, 928119 (2023).
Yu, J. I. et al. External validation of subclassification system and progression pattern analysis in hepatocelluar carcinoma with macroscopic vascular invasion. Radiother. Oncol. 187, 109841 (2023).
McDonald, S. A. et al. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?. J. Hepatol. 62, 262–268 (2015).
McDonald, S. A. et al. Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage study. Aliment. Pharmacol. Ther. 50, 425–434 (2019).
McAllister, G. et al. Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. J. Clin. Virol. 61, 359–364 (2014).
Mustafa, M. Z. et al. The efficacy and safety of treating hepatitis C in patients with a diagnosis of schizophrenia. J. Viral Hepat. 21, e48–e51 (2014).
Valerio, H. et al. Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: implications for reinfection. Drug Alcohol Depend. 154, 125–131 (2015).
Robles-Diaz, M. et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 147, 109–118.e5 (2014).
Robles-Diaz, M. et al. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. Liver Int. 35, 2474–2482 (2015).
Bessone, F. et al. Serious liver injury induced by Nimesulide: an international collaborative study. Arch. Toxicol. 95, 1475–1487 (2021).
Fernández, C. C. et al. Successful continuation of HCV treatment after liver transplantation. Transplantation 101, 1009–1012 (2017).
Fernández, C. C. et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry. Hepatology 65, 1810–1822 (2017).
Xu, L. et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J. Gastroenterol. Hepatol. 30, 1032–1039 (2015).
Engstrand, J., Stål, P., Gilg, S., Jansson, A. & Strömberg, C. Hepatocellular carcinoma in cirrhotic versus non-cirrhotic liver: treatment and survival differences in a nationwide cohort. Scand. J. Surg. 113, 120–130 (2024).
Alswat, K. et al. Clinical and metabolic characteristics of non-alcoholic fatty liver disease patients in Saudi Arabia: data from the Systematic Observatory Liver Disease (SOLID) Registry. Diabetes Metab. Syndr. Obes. 14, 1167–1175 (2021).
Yu, M. L. et al. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan. Hepatol. Int. 18, 461–475 (2024).
Lu, M.-Y. et al. Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: a nationwide hepatitis C virus registry program. Clin. Mol. Hepatol. 30, 64–79 (2023).
Chang, T. S. et al. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry. Hepatol. Int. 17, 550–561 (2023).
Chen, C. et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 41, 1265–1277 (2021).
Huang, C. F. et al. Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV registry program (TACR). Clin. Gastroenterol. Hepatol. 20, 1151–1162.e6 (2022).
Lo, C. C. et al. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: real-world evidence from a nationwide registry in Taiwan. J. Formos. Med. Assoc. 121, 1567–1578 (2022).
Chang, I. C. et al. The hepatitis viral status in patients with hepatocellular carcinoma: a study of 3843 patients from Taiwan Liver Cancer Network. Medicine 95, e3284 (2016).
Barritt, A. S. et al. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study. Contemp. Clin. trials 61, 33–38 (2017).
Chirapongsathorn, S. et al. Characteristics of drug-induced liver injury in chronic liver disease: results from the Thai Association for the Study of the Liver (THASL) DILI Registry. J. Clin. Transl. Hepatol. 11, 88–96 (2023).
Thanapirom, K. et al. Association of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: a multicentre study. Antivir. Ther. 23, 67–75 (2018).
Drysdale, K. et al. English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. Aliment. Pharmacol. Ther. 52, 168–181 (2020).
Schmeltzer, P. A. et al. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int. 36, 603–609 (2016).
Mahale, P. et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut 67, 553–561 (2018).
El-Serag, H. B., Kanwal, F., Davila, J. A., Kramer, J. & Richardson, P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 146, 1249–55.e1 (2014).
El-Serag, H. B., Kramer, J., Duan, Z. & Kanwal, F. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J. viral Hepat. 23, 687–696 (2016).
Rabiee, A. et al. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatol. Commun. 7, e0093 (2023).
Kaplan, D. E. et al. Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. Clin. Gastroenterol. Hepatol. 13, 2333–2341 (2015).
Iluz-Freundlich, D. et al. Spontaneous flares of chronic hepatitis b virus in hepatitis be antigen negative carriers who subsequently clear hepatitis B surface antigen. Dig. Dis. Sci. 66, 257–262 (2021).
Attia, D. et al. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study. Aliment. Pharmacol. Ther. 56, 1581–1590 (2022).
Wang, H. et al. Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis. J. Viral Hepat. 25, 930–938 (2018).
Wyber, R. et al. Big data in global health: improving health in low- and middle-income countries. Bull. World Health Organ. 93, 203–208 (2015).
Stanaway, J. D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388, 1081–1088 (2016).
Oni, T. et al. Global public health starts at home: upstream approaches to global health training. Lancet Glob. Health 7, e301–e302 (2019).
Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).
Jaacks, L. M. et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 7, 231–240 (2019).
Kostkova, P. et al. Who owns the data? Open data for healthcare. Front. Public Health 4, 7 (2016).
Jawhari, B., Ludwick, D., Keenan, L., Zakus, D. & Hayward, R. Benefits and challenges of EMR implementations in low resource settings: a state-of-the-art review. BMC Med. Inform. Decis. Mak. 16, 116 (2016).
van Panhuis, W. G. et al. A systematic review of barriers to data sharing in public health. BMC Public Health 14, 1144 (2014).
Tiangco, B. et al. Challenges in the maintenance of an open hospital-based cancer registry system in a low-to-middle-income country (LMIC): 2017-2022 experience. PLOS Digit. Health 3, e0000328 (2024).
Tan, A. L., Feliciano, E. J. G., Habaluyas, K. E. R., Bolong, N. P. & Wong, J. Q. Processes of creating a national cancer registry system in the Philippines. Electron. J. Inf. Syst. Dev. Ctries. 90, e12324 (2024).
Macrohon, B. C. et al. The design and development of a national registry of pediatric neurological diseases in the Philippines—a preliminary report. Philipp. J. Neurol. 21, 20–29 (2018).
Gliklich, R. E., Leavy, M. B. & Dreyer, N. A. Registries for Evaluating Patient Outcomes: A User’s Guide. (Agency for Healthcare Research and Quality (US), 2020).
Farhan, M. et al. National hepatitis registry in Pakistan: a dire need for hepatitis surveillance and control. Trop. Med. Health 51, 41 (2023).
Najibah, N. et al. Designing a mobile app for a national liver cancer registry in Bangladesh. in Lecture Notes in Computer Science 329–346 (Springer Nature Switzerland, 2025).
Danford, C. J. et al. A pathophysiologic approach combining genetics and insulin resistance to predict the severity of nonalcoholic fatty liver disease. Hepatol. Commun. 2, 1467–1478 (2018).
Zhang, M. et al. ‘Treat-all’ strategy for patients with Chronic Hepatitis B virus infection in China: are we there yet?. J. Clin. Transl. Hepatol. 12, 589–593 (2024).
Christensen, P. B. et al. Hepatitis C prevalence in Denmark—an estimate based on multiple national registers. BMC Infect. Dis. 12, 178 (2012).
Akkiz, H. et al. Macroscopic portal vein thrombosis in HCC patients. Can. J. Gastroenterol. Hepatol. 2018, 3120185 (2018).
Michel, M. et al. Lower incidence of HCC and other major adverse liver outcomes in people living with HIV and chronic liver disease. Gastro Hep Adv. 3, 783–792 (2024).
ClinicalTrials.gov. Study record NCT04442334. https://clinicaltrials.gov/study/NCT04442334.
Health Research Authority. European Paediatric NAFLD Registry (EU-PNAFLD). https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/european-paediatric-nafld-registry-eu-pnafld/.
Global Liver Council. Global Liver Registry. https://www.globallivercouncil.org/global-liver-registry/.
Global NASH Council. Global NASH Council. https://www.globalnashcouncil.org/.
Yopp, A. C. et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann. Surg. Oncol. 21, 1287–1295 (2014).
HCV-TARGET—Hepatitis C Therapeutic Registry and Research Network. Study record. https://ctv.veeva.com/study/hcv-target-hepatitis-c-therapeutic-registry-and-research-network.
Sumida, Y. et al. Non-invasive scoring systems for predicting NASH in Japan: evidences from Japan Study Group of NAFLD. Integr. Mol. Med. 2, 145–149 (2015).
Bessone, F. et al. Drug-induced liver injury in Latin America: 10-year experience of the Latin American DILI (LATINDILI) Network. Clin. Gastroenterol. Hepatol. 23, 89–102 (2025).
Viganò, L. LiverMetSurvey registry: The Italian experience. in Surgical Treatment of Colorectal Liver Metastases 165–182 (Springer Milan, 2011).
NASH Clinical Research Network (NASH CRN). NASH Clinical Research Network. https://gastroenterology.ucsd.edu/research/labs/fatty-liver/research/epidemiology/nash-crn.html.
Reuben, A. et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann. Intern. Med. 164, 724–732 (2016).
Acute Liver Failure Study Group. https://labs.utsouthwestern.edu/acute-liver-failure-study-group/research.
Lepage, C. et al. Telemedicine successfully engages marginalized rural hepatitis C patients in curative care. J. Assoc. Med. Microbiol. Infect. Dis. Can. 5, 87–97 (2020).
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Study Repository. https://repository.niddk.nih.gov/study/45.
Cartabellotta, F., Di Marco, V. & RESIST - HCV The HCV Sicily Network: a web-based model for the management of HCV chronic liver diseases. Eur. Rev. Med. Pharmacol. Sci. 20, 11–16 (2016).
Calvaruso, V. et al. Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. J. Viral Hepat. 28, 1190–1199 (2021).
Sinn, D. H. et al. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS ONE 10, e0124434 (2015).
Public Health Scotland. Scottish Hepatitis C Virus (HCV) Clinical Database. https://publichealthscotland.scot/resources-and-tools/health-intelligence-and-data-management/national-data-catalogue/national-datasets/search-the-datasets/scottish-hepatitis-c-virus-hcv-clinical-database/.
Spanish DILI Registry. Herramientas Para Colaborar. https://www.spanishdili.uma.es/index.php/colaborar/herramientas-para-colaborar.
Swedish Quality Registry Group for Liver, Bile Duct and Gallbladder Cancer. National Quality Registry Group—Liver, Bile Ducts And Gallbladder Cancer. https://cancercentrum.se/samverkan/cancerdiagnoser/lever-och-galla/kvalitetsregister/registergrupp/.
Abdo, A. A. et al. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann. Saudi Med. 32, 174–199 (2012).
SOLID Registry. SOLID—Liver Registry. https://www.solid-registry.com/home%20from.
TARGET-NASH. TARGET-NASH Registry. https://www.targetrwe.com/unique-data/registries/target-nash/.
UK Department of Health and Social Care. Hepatitis C National Register. https://www.gov.uk/government/publications/hepatitis-c-national-register.
Chalasani, N. et al. Drug induced liver injury network (DILIN) prospective study. Am. J. Gastroenterol. 101, S169 (2006).
Drug-Induced Liver Injury Network (DILIN). DILIN. Available from: https://dilin.org/.
John, B. V. et al. Liver stiffness measurement and risk prediction of hepatocellular carcinoma after HCV eradication in veterans with cirrhosis. Clin. Gastroenterol. Hepatol. 22, 778–788.e7 (2024).
Van Iderstine, M. G., Uhanova, J. & Minuk, G. Y. Liver enzymes and fibrosis markers in patients with non-alcoholic fatty liver disease and concomitant chronic viral hepatitis. Can. Liver J. 4, 317–321 (2021).
来源:Nature 健康护理主题 · nature.com